Winston-Salem, NC-based PointDx is a step closer to entering the U.S. market with a structured reporting technology following the FDA clearance of its REX workstation (version 1.0). REX seamlessly integrates structured reporting with 2D and 3D image
Winston-Salem, NC-based PointDx is a step closer to entering the U.S. market with a structured reporting technology following the FDA clearance of its REX workstation (version 1.0). REX seamlessly integrates structured reporting with 2D and 3D image analysis. The technology promises to improve report turnaround time, reducing overall reporting costs and providing more concise yet comprehensive information than is possible with traditional reporting models (see feature article, this issue). Completed multimedia reports are made available instantaneously to referring physicians, who can see patient information, diagnostic findings, and images in reports delivered over a secure Internet connection. The system is designed to replicate current reporting workflow, but it automates the process to eliminate many of the inefficiencies associated with traditional reporting. Reports are accompanied by embedded images.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.